MCID: GLM045
MIFTS: 64

Glioma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Glioma

MalaCards integrated aliases for Glioma:

Name: Glioma 53 37 29 55 6 17 72

Classifications:



External Ids:

KEGG 37 H00042
UMLS 72 C0017638

Summaries for Glioma

KEGG : 37
Gliomas are the most common of the primary brain tumors and account for more than 40% of all central nervous system neoplasms. Gliomas include tumours that are composed predominantly of astrocytes (astrocytomas), oligodendrocytes (oligodendrogliomas), mixtures of various glial cells (for example,oligoastrocytomas) and ependymal cells (ependymomas). The most malignant form of infiltrating astrocytoma - glioblastoma multiforme (GBM) - is one of the most aggressive human cancers. GBM may develop de novo (primary glioblastoma) or by progression from low-grade or anaplastic astrocytoma (secondary glioblastoma). Primary glioblastomas develop in older patients and typically show genetic alterations (EGFR amplification, p16/INK4a deletion, and PTEN mutations) at frequencies of 24-34%. Secondary glioblastomas develop in younger patients and frequently show overexpression of PDGF and CDK4 as well as p53 mutations (65%) and loss of Rb playing major roles in such transformations. Loss of PTEN has been implicated in both pathways, although it is much more common in the pathogenesis of primary GBM.

MalaCards based summary : Glioma is related to malignant glioma and astrocytoma. An important gene associated with Glioma is MIR21 (MicroRNA 21), and among its related pathways/superpathways are Glioma and MicroRNAs in cancer. The drugs Midazolam and Trametinib have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial.

NIH Rare Diseases : 53 Glioma refers to a type of brain tumor that develops from the glial cells, which are specialized cells that surround and support neurons (nerve cells) in the brain. It is generally classified based on which type of glial cell is involved in the tumor: Astocytoma - tumors that develop from star-shaped glial cells called astrocytes Ependymomas - tumors that arise from ependymal cells that line the ventricles of the brain and the center of the spinal cord Oligodendrogliomas - tumors that affect the oligodendrocytes The symptoms of glioma vary by type but may include headaches; nausea and vomiting; confusion; personality changes; trouble with balance; vision problems; speech difficulties; and/or seizures. The exact underlying cause is unknown. In most cases, the tumor occurs sporadically in people with no family history of the condition. Treatment depends on many factors, including the type, size, stage and location of the tumor, but may include surgery, radiation therapy, chemotherapy and/or targeted therapy.

Wikipedia : 75 A glioma is a type of tumor that starts in the glial cells of the brain or the spine. Gliomas comprise... more...

Related Diseases for Glioma

Diseases in the Glioma family:

Malignant Glioma

Diseases related to Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1093)
# Related Disease Score Top Affiliating Genes
1 malignant glioma 35.0 PVT1 NEAT1 HOTAIR CDKN2B-AS1
2 astrocytoma 34.0 MIR21 LINC00461 HOTAIR H19
3 retinoblastoma 33.3 MIR34A MEG3 MALAT1 HOTAIR
4 glioblastoma 32.7 MIR34A MIR296 MIR222 MIR221 MIR21 MIR181A2
5 medulloblastoma 31.9 MIR34A MIR17 HOTAIR H19 CDKN2B-AS1
6 pituitary adenoma 31.7 MEG3 MALAT1 HOTAIR H19
7 leukemia, acute lymphoblastic 31.6 MIR222 MIR221 MIR21
8 osteogenic sarcoma 31.2 UCA1 PVT1 NEAT1 MEG3 MALAT1 HOTAIR
9 renal cell carcinoma, nonpapillary 31.1 UCA1 PVT1 MALAT1 HOTAIR H19
10 lung cancer susceptibility 3 31.1 MEG3 MALAT1 HOTAIR H19
11 bladder cancer 31.0 UCA1 PVT1 MIR222 MIR221 MIR21 MEG3
12 squamous cell carcinoma 31.0 UCA1 NEAT1 MALAT1 HOTAIR H19 CDKN2B-AS1
13 acute promyelocytic leukemia 31.0 PVT1 NEAT1 MIR221 MIR15B
14 diffuse large b-cell lymphoma 30.9 MIR221 MIR21 HOTAIR
15 small cell cancer of the lung 30.9 MIR21 MALAT1 HOTAIR
16 melanoma 30.8 UCA1 PVT1 MIR34A MIR222 MIR221 MIR184
17 leukemia, acute myeloid 30.7 UCA1 MIR222 MIR221 MIR21 MIR184 MIR181A2
18 clear cell renal cell carcinoma 30.7 PVT1 MIR21 MEG3 MALAT1
19 nasopharyngeal carcinoma 30.7 PVT1 NEAT1 MEG3 MALAT1 HOTAIR H19
20 congestive heart failure 30.7 MIR21 HOTAIR CDKN2B-AS1
21 myeloma, multiple 30.7 UCA1 PVT1 MIR181A2 MEG3 MALAT1 HOTAIR
22 kidney cancer 30.7 PVT1 MIR21 MIR17 MEG3 MALAT1 HOTAIR
23 esophageal cancer 30.6 UCA1 PVT1 MIR34A MIR21 MEG3 MALAT1
24 ovarian epithelial cancer 30.6 MEG3 MALAT1 HOTAIR H19
25 parkinson disease, late-onset 30.6 NEAT1 MALAT1 HOTAIR H19
26 pancreatic ductal adenocarcinoma 30.6 UCA1 PVT1 MIR221 MIR21 MALAT1 HOTAIR
27 diabetes mellitus 30.6 PVT1 MIR34A MIR181A2 MEG3 MALAT1 CDKN2B-AS1
28 hepatocellular carcinoma 30.6 UCA1 PVT1 NEAT1 MIR34A MIR222 MIR221
29 endometrial cancer 30.5 UCA1 NEAT1 MEG3 HOTAIR H19 FOXO1
30 tongue squamous cell carcinoma 30.5 UCA1 MIR222 MIR21 MEG3 MALAT1
31 breast cancer 30.5 UCA1 PVT1 NEAT1 MIR34A MIR222 MIR221
32 lung cancer 30.5 UCA1 PVT1 NEAT1 MIR34A MIR222 MIR221
33 leukemia, chronic myeloid 30.4 UCA1 MEG3 HOTAIR H19
34 laryngeal squamous cell carcinoma 30.4 NEAT1 MIR21 MALAT1 HOTAIR H19 CDKN2B-AS1
35 cholangiocarcinoma 30.4 UCA1 NEAT1 MIR21 MALAT1 H19
36 colorectal cancer 30.4 UCA1 PVT1 NEAT1 MIR34A MIR296 MIR221
37 pancreatic cancer 30.4 UCA1 PVT1 NEAT1 MIR34A MIR222 MIR221
38 gallbladder cancer 30.4 UCA1 MEG3 MALAT1 HOTAIR H19 CDKN2B-AS1
39 gastric cancer 30.4 UCA1 PVT1 NEAT1 MIR34A MIR222 MIR221
40 cervical cancer 30.3 UCA1 PVT1 NEAT1 MIR21 MEG3 MALAT1
41 ovarian cancer 30.2 UCA1 PVT1 NEAT1 MIR296 MIR222 MIR221
42 prostate cancer 30.2 UCA1 PVT1 NEAT1 MIR34A MIR296 MIR222
43 thyroid cancer, nonmedullary, 1 30.1 PVT1 NEAT1 MIR34A MIR222 MIR221 MIR181A2
44 prostatic hyperplasia, benign 30.1 UCA1 CDKN2B-AS1
45 oral squamous cell carcinoma 29.8 UCA1 NEAT1 MIR34A MIR296 MIR221 MIR21
46 myelofibrosis 29.7 MIR146B MEG3 CDKN2B-AS1
47 glioma susceptibility 1 12.7
48 diffuse intrinsic pontine glioma 12.6
49 optic nerve glioma 12.6
50 brain stem glioma 12.6

Graphical network of the top 20 diseases related to Glioma:



Diseases related to Glioma

Symptoms & Phenotypes for Glioma

Drugs & Therapeutics for Glioma

Drugs for Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 587)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
2
Trametinib Approved Phase 4 871700-17-3 11707110
3
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
4
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
5 Neurotransmitter Agents Phase 4
6 Anti-Anxiety Agents Phase 4
7 Excitatory Amino Acid Antagonists Phase 4
8 Excitatory Amino Acids Phase 4
9 alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Phase 4
10 Excitatory Amino Acid Agonists Phase 4
11
Dextroamphetamine Approved, Illicit Phase 3 51-64-9 5826
12
Lenograstim Approved, Investigational Phase 3 135968-09-1
13
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
14
Carmustine Approved, Investigational Phase 3 154-93-8 2578
15
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
16
Dalteparin Approved Phase 3 9005-49-6
17
Somatostatin Approved, Investigational Phase 2, Phase 3 38916-34-6, 51110-01-1 53481605
18
Ondansetron Approved Phase 3 99614-02-5 4595
19
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
20
Trioxsalen Approved Phase 3 3902-71-4 5585
21
Donepezil Approved Phase 3 120014-06-4 3152
22
Thioguanine Approved Phase 3 154-42-7 2723601
23
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
24
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
25
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
26
Ethanol Approved Phase 2, Phase 3 64-17-5 702
27
Disulfiram Approved Phase 2, Phase 3 97-77-8 3117
28
Copper Approved, Investigational Phase 2, Phase 3 7440-50-8 27099
29
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
30
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
31
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
32
Irinotecan Approved, Investigational Phase 3 100286-90-6, 97682-44-5 60838
33
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
34
Etoposide Approved Phase 3 33419-42-0 36462
35
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
36
Histamine Approved, Investigational Phase 3 51-45-6 774
37
leucovorin Approved Phase 3 58-05-9 143 6006
38
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
39
Cyproheptadine Approved Phase 3 129-03-3 2913
40
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
41
Norepinephrine Approved Phase 3 51-41-2 439260
42
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
43
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
44
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
45 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
46 Dianhydrogalactitol Investigational Phase 3 23261-20-3
47 Heparin, Low-Molecular-Weight Phase 3
48 calcium heparin Phase 3
49 Central Nervous System Depressants Phase 3
50 Endothelial Growth Factors Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 1349)
# Name Status NCT ID Phase Drugs
1 A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection Completed NCT02193568 Phase 4
2 Phase II Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
3 Seizure Treatment IN Glioma (STING): Comparing a Treatment Strategy With Levetiracetam Versus Treatment With Valproic Acid in Glioma Patients With a First Seizure Recruiting NCT03048084 Phase 4 Levetiracetam;Valproic Acid
4 Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
5 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Not yet recruiting NCT03975829 Phase 4 dabrafenib;trametinib
6 A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
7 Cognitive Rehabilitation of Glioma Patients: a Prospective, Randomized Study Unknown status NCT00256425 Phase 3
8 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Unknown status NCT02892708 Phase 3
9 Prospective Randomized Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Pediatric Diffuse Brainstem Glioma Unknown status NCT01878266 Phase 3
10 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
11 A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial Unknown status NCT02363075 Phase 3 Dexamfetamine sulphate;placebo
12 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
13 Barrow 5-ALA Intraoperative Confocal Evaluation Trial Unknown status NCT01502280 Phase 3 5-Aminolevulinic acid (ALA);Placebo - ascorbic acid
14 A Prospective, Randomized, Controlled, Double-blind, Multi-center Clinical Study of Nimotuzumab Combinated With Gemcitabine Contrast to Placebo Combinated With Gemcitabine in K-RAS Wild-type,Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine
15 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
16 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
17 A Prospective,Randomized,Double-Blind,Controlled,Multicenter,Phase III Study of Nimotuzumab in Combination With Chemotherapy and Radiotherapy for Patients With Local Advanced Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
18 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
19 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
20 PET/CT Imaging of Malignant Glioma With Somatostatin Analog 68Ga-DOTATOC Completed NCT01460706 Phase 2, Phase 3 [68Ga]DOTATOC
21 A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE) Completed NCT00135876 Phase 3 dalteparin
22 Clinical Study to Assess the Positive Predictive Value of NPC-07 Induced Tissue Fluorescence in Patients With Malignant Glioma (WHO Grades III/IV) Completed NCT01167322 Phase 3 NPC-07 for oral administration
23 Prospective Randomized Trial of Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children. Completed NCT01635140 Phase 3
24 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
25 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
26 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
27 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
28 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
29 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
30 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
31 Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
32 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection Completed NCT00241670 Phase 3 5-aminolevulinic acid (5-ALA)
33 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
34 A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
35 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
36 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
37 Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
38 PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
39 PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
40 Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
41 A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREATMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER Completed NCT00561990 Phase 2, Phase 3 Nimotuzumab
42 Chloroquine as Adjuvant to the Treatment of Glioblastoma Multiforme, A Randomized Trial Completed NCT00224978 Phase 3 Chloroquine
43 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
44 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
45 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3 β-elemene
46 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3 Temozolomide;α-IFN
47 A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy Recruiting NCT02796261 Phase 3 Eflornithine;Lomustine;Lomustine
48 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
49 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
50 Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy - A Prospective Follow-up Study Recruiting NCT03534050 Phase 2, Phase 3

Search NIH Clinical Center for Glioma

Genetic Tests for Glioma

Genetic tests related to Glioma:

# Genetic test Affiliating Genes
1 Glioma 29

Anatomical Context for Glioma

MalaCards organs/tissues related to Glioma:

41
Brain, T Cells, Endothelial, Spinal Cord, Bone, Testes, Retina

Publications for Glioma

Articles related to Glioma:

(show top 50) (show all 31023)
# Title Authors PMID Year
1
MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. 9 38 88
19773441 2009
2
Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. 9 38 88
19424584 2009
3
MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. 9 38 88
18591254 2008
4
Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. 38 88
19775293 2010
5
MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. 38 88
19536818 2009
6
microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs. 38 88
19265686 2009
7
MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells. 38 88
19135980 2009
8
miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. 38 88
18977327 2008
9
hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. 38 88
18710654 2008
10
MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. 38 88
17908999 2007
11
JNK mediates insulin-like growth factor binding protein 2/integrin alpha5-dependent glioma cell migration. 9 38
20514406 2010
12
AKT2 expression is associated with glioma malignant progression and required for cell survival and invasion. 9 38
20514445 2010
13
Intussusceptive microvascular growth in human glioma. 9 38
19882213 2010
14
Combination therapy with Gamma Knife radiosurgery and antisense EGFR for malignant glioma in vitro and orthotopic xenografts. 9 38
20428813 2010
15
Gene expression profiling predicts response to temozolomide in malignant gliomas. 9 38
20428759 2010
16
Induction of S100B secretion in C6 astroglial cells by the major metabolites accumulating in glutaric acidemia type I. 9 38
20437086 2010
17
Glioma cell populations grouped by different cell type markers drive brain tumor growth. 9 38
20460538 2010
18
Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma. 9 38
20382206 2010
19
A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics. 9 38
20375153 2010
20
The carboxy-terminal tail of connexin43 gap junction protein is sufficient to mediate cytoskeleton changes in human glioma cells. 9 38
20512920 2010
21
Immunohistochemical expression of stem cell, endothelial cell, and chemosensitivity markers in primary glioma spheroids cultured in serum-containing and serum-free medium. 9 38
20404698 2010
22
Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. 9 38
19856144 2010
23
Increased expression of Akt2 and activity of PI3K and cell proliferation with the ascending of tumor grade of human gliomas. 9 38
20116920 2010
24
FasL gene knock-down therapy enhances the antiglioma immune response. 9 38
20406899 2010
25
Human neural stem cells transduced with IFN-beta and cytosine deaminase genes intensify bystander effect in experimental glioma. 9 38
19893595 2010
26
Nodal promotes growth and invasion in human gliomas. 9 38
20383200 2010
27
Human umbilical cord blood stem cells show PDGF-D-dependent glioma cell tropism in vitro and in vivo. 9 38
20406896 2010
28
Induction of apoptosis in glioma cells requires cell-to-cell contact with human umbilical cord blood stem cells. 9 38
20372790 2010
29
Imaging of human glioma cells by means of a Syndecan-4 directed DOTA-conjugate. 9 38
19777324 2010
30
Akt signaling pathway: a target for radiosensitizing human malignant glioma. 9 38
20406894 2010
31
RECK-mediated inhibition of glioma migration and invasion. 9 38
20127710 2010
32
Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner. 9 38
20442305 2010
33
CD40 is a regulator for vascular endothelial growth factor in the tumor microenvironment of glioma. 9 38
20303602 2010
34
Bradykinin-induced cell migration and COX-2 production mediated by the bradykinin B1 receptor in glioma cells. 9 38
20411591 2010
35
TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner. 9 38
20093382 2010
36
Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival. 9 38
19810093 2010
37
Astrocyte elevated gene-1 upregulates matrix metalloproteinase-9 and induces human glioma invasion. 9 38
20388776 2010
38
Genetic variants in inflammation pathway genes and asthma in glioma susceptibility. 9 38
20406895 2010
39
Clinical and biological significance of forkhead class box O 3a expression in glioma: mediation of glioma malignancy by transcriptional regulation of p27kip1. 9 38
19911116 2010
40
Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas. 9 38
19626585 2010
41
Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation. 9 38
20233866 2010
42
Target gene therapy of glioma: overexpression of BAX gene under the control of both tissue-specific promoter and hypoxia-inducible element. 9 38
20383466 2010
43
Molecular interaction and functional regulation of ClC-3 by Ca2+/calmodulin-dependent protein kinase II (CaMKII) in human malignant glioma. 9 38
20139089 2010
44
Glycitein inhibits glioma cell invasion through down-regulation of MMP-3 and MMP-9 gene expression. 9 38
20188714 2010
45
Erratum to: Hepatocyte growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells. 9 38
20119650 2010
46
Cooperative expression of junctional adhesion molecule-C and -B supports growth and invasion of glioma. 9 38
19795504 2010
47
The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. 9 38
20388803 2010
48
Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. 9 38
20308316 2010
49
Peptide-based interference of the transmembrane domain of neuropilin-1 inhibits glioma growth in vivo. 9 38
20140015 2010
50
Nestin expression in astrocytic tumors delineates tumor infiltration. 9 38
20425043 2010

Variations for Glioma

ClinVar genetic disease variations for Glioma:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 subset of 191 genes:ELAVL2 ; HNRNPK complex Likely pathogenic 9:23524426-87359888 :0-0

Cosmic variations for Glioma:

9 (show top 50) (show all 7141)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM40802 ZW10 central nervous system,brain,glioma,astrocytoma c.2140C>T p.P714S 11:113736699-113736699 8
2 COSM40801 ZSWIM4 central nervous system,brain,glioma,astrocytoma c.266C>T p.P89L 19:13799832-13799832 8
3 COSM6932117 ZRSR2 central nervous system,brain,glioma,astrocytoma c.271G>A p.E91K 23:15803755-15803755 8
4 COSM6948317 ZRSR2 central nervous system,brain,glioma,astrocytoma c.340C>T p.Q114* 23:15804138-15804138 8
5 COSM6959574 ZRSR2 central nervous system,brain,glioma,astrocytoma c.260G>A p.R87K 23:15803744-15803744 8
6 COSM6932118 ZRSR2 central nervous system,brain,glioma,astrocytoma c.961C>T p.P321S 23:15822754-15822754 8
7 COSM6973162 ZRSR2 central nervous system,brain,glioma,oligodendroglioma Grade III c.220G>A p.E74K 23:15803704-15803704 8
8 COSM39611 ZPLD1 central nervous system,brain,glioma,astrocytoma c.393A>T p.G131G 3:102456210-102456210 8
9 COSM40237 ZNF687 central nervous system,brain,glioma,astrocytoma c.3651C>T p.T1217T 1:151291146-151291146 8
10 COSM39318 ZNF687 central nervous system,brain,glioma,astrocytoma c.2044T>A p.C682S 1:151288335-151288335 8
11 COSM39317 ZNF687 central nervous system,brain,glioma,astrocytoma c.2043G>C p.Q681H 1:151288334-151288334 8
12 COSM39149 ZNF507 central nervous system,brain,glioma,astrocytoma c.1517G>C p.R506T 19:32354347-32354347 8
13 COSM40794 ZNF473 central nervous system,brain,glioma,astrocytoma c.42C>T p.D14D 19:50039193-50039193 8
14 COSM39217 ZMYND8 central nervous system,brain,glioma,astrocytoma c.2162T>G p.V721G 20:47246130-47246130 8
15 COSM40504 ZMYND8 central nervous system,brain,glioma,astrocytoma c.2176G>A p.D726N 20:47246116-47246116 8
16 COSM5977723 ZMYM2 central nervous system,spinal cord,glioma,astrocytoma Grade I c.1134-1G>T p.? 13:20005073-20005073 8
17 COSM5977724 ZMYM2 central nervous system,spinal cord,glioma,astrocytoma Grade I c.1134-1G>T p.? 13:20005073-20005073 8
18 COSM39507 ZMAT4 central nervous system,brain,glioma,astrocytoma c.76G>A p.E26K 8:40825601-40825601 8
19 COSM6976869 ZFHX3 central nervous system,brain,glioma,astrocytoma c.4279G>A p.A1427T 16:72798403-72798403 8
20 COSM6929045 ZFHX3 central nervous system,brain,glioma,astrocytoma c.3607G>T p.E1203* 16:72811961-72811961 8
21 COSM6950242 ZFHX3 central nervous system,brain,glioma,oligodendroglioma Grade III c.8300G>A p.G2767E 16:72794382-72794382 8
22 COSM6959528 ZFHX3 central nervous system,brain,glioma,astrocytoma c.145C>T p.P49S 16:72960001-72960001 8
23 COSM5385367 ZFHX3 central nervous system,brain,glioma,astrocytoma c.934G>A p.D312N 16:72959212-72959212 8
24 COSM6980194 ZFHX3 central nervous system,brain,glioma,oligodendroglioma Grade III c.6025T>C p.Y2009H 16:72796657-72796657 8
25 COSM5981027 ZFHX3 central nervous system,brain,glioma,astrocytoma c.8647A>G p.M2883V 16:72794035-72794035 8
26 COSM3888943 ZFHX3 central nervous system,brain,glioma,astrocytoma c.8198G>A p.R2733H 16:72794484-72794484 8
27 COSM6973145 ZFHX3 central nervous system,brain,glioma,oligodendroglioma Grade III c.3986G>A p.G1329E 16:72798696-72798696 8
28 COSM6976663 ZFHX3 central nervous system,brain,glioma,oligodendroglioma Grade III c.8600C>T p.S2867F 16:72794082-72794082 8
29 COSM6968504 ZFHX3 central nervous system,brain,glioma,oligodendroglioma Grade III c.2680G>A p.D894N 16:72957466-72957466 8
30 COSM6976870 ZFHX3 central nervous system,brain,glioma,astrocytoma c.461G>A p.G154E 16:72959685-72959685 8
31 COSM6948292 ZFHX3 central nervous system,brain,glioma,astrocytoma c.1819G>A p.E607K 16:72958327-72958327 8
32 COSM6968503 ZFHX3 central nervous system,brain,glioma,oligodendroglioma Grade III c.9154G>A p.V3052I 16:72793528-72793528 8
33 COSM40870 ZFC3H1 central nervous system,brain,glioma,astrocytoma c.1055G>A p.S352N 12:71647774-71647774 8
34 COSM40793 ZFAT central nervous system,brain,glioma,astrocytoma c.1006G>A p.V336M 8:134602677-134602677 8
35 COSM40680 ZEB1 central nervous system,brain,glioma,astrocytoma c.1913C>T p.S638L 10:31521248-31521248 8
36 COSM41152 ZC3H6 central nervous system,brain,glioma,astrocytoma c.2254G>T p.G752* 2:112331172-112331172 8
37 COSM40778 ZBTB4 central nervous system,brain,glioma,astrocytoma c.2842C>T p.L948F 17:7462140-7462140 8
38 COSM40777 ZBTB24 central nervous system,brain,glioma,astrocytoma c.1886C>T p.P629L 6:109466059-109466059 8
39 COSM39508 ZBTB21 central nervous system,brain,glioma,astrocytoma c.997G>A p.G333S 21:41993099-41993099 8
40 COSM40776 ZBTB16 central nervous system,brain,glioma,astrocytoma c.413C>T p.A138V 11:114063713-114063713 8
41 COSM41039 YWHAH central nervous system,brain,glioma,astrocytoma c.169C>T p.R57* 22:31956220-31956220 8
42 COSM40774 YTHDC2 central nervous system,brain,glioma,astrocytoma c.782C>T p.A261V 5:113532985-113532985 8
43 COSM4440509 YES1 central nervous system,brain,glioma,astrocytoma c.832C>T p.R278* 18:743308-743308 8
44 COSM6913717 YES1 central nervous system,brain,glioma,astrocytoma c.1153G>A p.A385T 18:736946-736946 8
45 COSM6919634 YES1 central nervous system,brain,glioma,oligodendroglioma Grade III c.259G>C p.A87P 18:756569-756569 8
46 COSM6931893 YAP1 central nervous system,brain,glioma,astrocytoma c.1007C>T p.T336I 11:102227474-102227474 8
47 COSM6928995 YAP1 central nervous system,brain,glioma,astrocytoma c.842G>A p.R281Q 11:102206046-102206046 8
48 COSM6962767 YAP1 central nervous system,brain,glioma,astrocytoma c.538G>A p.A180T 11:102114360-102114360 8
49 COSM6976817 XRCC2 central nervous system,brain,glioma,astrocytoma c.365G>A p.S122N 7:152649120-152649120 8
50 COSM39272 XPO7 central nervous system,brain,glioma,astrocytoma c.1157G>A p.R386Q 8:21982692-21982692 8

Copy number variations for Glioma from CNVD:

7 (show top 50) (show all 1065)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13321 2 208809197 208828051 Copy number IDH1 Glioma
2 14132 1 10403401 10408000 Deletion Glioma
3 14198 1 105227801 105232100 Deletion Glioma
4 15004 1 111800000 116100000 Deletion Glioma
5 15199 1 113411001 113417300 Deletion BC037540 Glioma
6 15250 1 113839501 113849000 Deletion Glioma
7 15641 1 117679901 117685200 Deletion Glioma
8 15695 1 118394101 118397900 Deletion Glioma
9 19119 1 148648801 148652600 Deletion Glioma
10 19806 1 151480801 151485400 Deletion Glioma
11 20843 1 154791301 154797500 Deletion IQGAP3 Glioma
12 21174 1 157132201 157138600 Deletion Glioma
13 21291 1 157913501 157918300 Deletion Glioma
14 21685 1 160317401 160321200 Deletion Glioma
15 23692 1 173061201 173070300 Deletion Glioma
16 24042 1 174742901 174746800 Deletion Glioma
17 24302 1 178448601 178452400 Deletion Glioma
18 25156 1 185029601 185033600 Deletion Glioma
19 25220 1 185729601 185734900 Deletion Glioma
20 25241 1 185980701 185991100 Deletion Glioma
21 25290 1 186804101 186808700 Deletion Glioma
22 25655 1 192615401 192619700 Deletion Glioma
23 26024 1 195765301 195771800 Deletion Glioma
24 26054 1 196268601 196275300 Deletion Glioma
25 26178 1 197703301 197708700 Deletion Glioma
26 26883 1 20368201 20372100 Deletion PLA2G2C Glioma
27 26979 1 204445801 204451500 Deletion Glioma
28 27209 1 205357001 205361800 Deletion Glioma
29 27636 1 210535701 210541200 Deletion Glioma
30 27909 1 215522601 215526900 Deletion Glioma
31 27938 1 216247201 216257200 Deletion Glioma
32 27948 1 216310301 216315100 Deletion Glioma
33 28054 1 217987801 217992100 Deletion Glioma
34 28169 1 219443901 219451100 Deletion Glioma
35 28238 1 220438701 220448900 Deletion Glioma
36 28860 1 226089101 226092600 Deletion Glioma
37 29433 1 232027401 232031900 Deletion Glioma
38 29707 1 234613701 234620000 Deletion Glioma
39 29744 1 234984301 234988400 Deletion ACTN2 Glioma
40 29950 1 238457901 238463400 Deletion Glioma
41 29974 1 238682401 238685500 Deletion Glioma
42 30033 1 239425501 239429300 Deletion Glioma
43 30273 1 241490101 241494000 Deletion Glioma
44 30527 1 244220301 244224400 Deletion Glioma
45 30564 1 244503701 244507900 Deletion Glioma
46 30805 1 246116501 246126100 Deletion OR2W3 Glioma
47 31058 1 25029301 25036000 Deletion Glioma
48 31536 1 28129101 28135200 Deletion SMPDL3B Glioma
49 31728 1 30200000 32400000 Deletion Glioma
50 33111 1 42513801 42517800 Deletion FOXJ3 Glioma

Expression for Glioma

Search GEO for disease gene expression data for Glioma.

Pathways for Glioma

Pathways related to Glioma according to KEGG:

37
# Name Kegg Source Accession
1 Glioma hsa05214
2 MicroRNAs in cancer hsa05206

Pathways related to Glioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.66 MIR34A MIR222 MIR221 MIR21 MIR181A2 MIR17
2 11.13 MIR222 MIR221 MIR15B
3 10.84 MIR222 MIR221 MIR181A2 MIR146B
4 10.41 UCA1 MEG3 HOTAIR

GO Terms for Glioma

Biological processes related to Glioma according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.93 MIR221 MIR21 MIR15B FOXO1
2 negative regulation of gene expression GO:0010629 9.88 MIR21 MIR181A2 MIR17 CDKN2B-AS1
3 positive regulation of protein kinase B signaling GO:0051897 9.83 MIR222 MIR221 MIR21
4 cellular response to hypoxia GO:0071456 9.79 MIR34A MIR17 MALAT1
5 negative regulation of angiogenesis GO:0016525 9.71 MIR34A MIR222 MIR21 MIR15B
6 positive regulation of epithelial to mesenchymal transition GO:0010718 9.67 MIR222 MIR221 MIR21
7 positive regulation of erythrocyte differentiation GO:0045648 9.65 MIR222 MIR221
8 negative regulation of vascular endothelial cell proliferation GO:1905563 9.65 MIR34A MIR15B
9 chromatin silencing GO:0006342 9.65 HOTAIR CDKN2B-AS1
10 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.64 MIR222 MIR15B
11 regulation of reactive oxygen species metabolic process GO:2000377 9.64 MIR21 FOXO1
12 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.63 MIR221 MIR21
13 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.62 MIR34A MIR21
14 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.61 MIR222 MIR221
15 positive regulation of endothelial cell differentiation GO:0045603 9.61 MIR21 MIR181A2
16 negative regulation of sprouting angiogenesis GO:1903671 9.61 MIR34A MIR221 MIR17
17 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.6 MIR34A MIR17
18 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.59 MIR21 MIR17
19 positive regulation of connective tissue replacement GO:1905205 9.58 MIR34A MIR15B
20 negative regulation of vascular smooth muscle cell differentiation GO:1905064 9.57 MIR221 MIR15B
21 positive regulation of metalloendopeptidase activity GO:1904685 9.56 MIR21 MIR17
22 positive regulation of axon regeneration GO:0048680 9.55 MIR222 MIR221
23 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.54 MIR21 MIR17
24 negative regulation by host of viral genome replication GO:0044828 9.52 MIR222 MIR221
25 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.51 MIR222 MIR221
26 negative regulation of cell adhesion molecule production GO:0060354 9.48 MIR222 MIR221
27 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.46 MIR222 MIR221
28 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.46 MIR222 MIR221 MIR21 MIR17
29 gene silencing by miRNA GO:0035195 9.44 NEAT1 MIR34A MIR296 MIR222 MIR221 MIR21
30 miRNA mediated inhibition of translation GO:0035278 9.43 MIR222 MIR221 MIR21 MIR181A2 MIR17 MIR15B
31 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.37 MIR222 MIR221
32 positive regulation of Schwann cell migration GO:1900149 9.32 MIR222 MIR221
33 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.26 MIR222 MIR221

Molecular functions related to Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.28 MIR34A MIR296 MIR222 MIR221 MIR21 MIR181A2

Sources for Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....